Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

FACT... $IPIX road to success with NO failed trials to date...




There were 137,874,421 and -0- shares, respectively, of the registrant’s $0.0001 par value Class A and Class B common stock outstanding as of September 1, 2017.

That is amazing restraint and consideration to ALL shareholders.



https://www.sec.gov/Archives/edgar/data/1355250/000147793217004400/ipix_10k.htm



OVERVIEW

Innovation has developed three lead drug candidates—each with first-in-class potential across multiple clinical indications attributable to novel mechanisms of action—with dermatology, oncology, anti-inflammatory and antibiotic applications.
•Prurisol—an orally-delivered medicine for treating psoriasis
•Kevetrin—a non-genotoxic anti-cancer drug that modulates p53
•Brilacidin—an immunomodulatory agent with anti-inflammatory/antibiotic properties

Based on sound science, and covered by strong intellectual property and patent protections, these drug candidates are in mid-to-late stage clinical trials.

Advancing under a number of special FDA designations to help expedite development, improve likelihood of drug approval and gain market exclusivity, they address large areas of unmet medical need and represent sizable commercial opportunities.


From Sox's post...

Past Milestones

Kevetrin

- Positive primary endpoint and p21 data (Phase 1)
http://www.ipharminc.com/press-release/2016/11/12/assay-results-from-cellceutix-phase-1-clinical-trial-of-kevetrin-for-cancer-show-increased-p21-expression-in-675-of-evaluable-patients

- Orphan drug designation for ovarian cancer
http://www.ipharminc.com/press-release/2016/11/16/cellceutixs-kevetrin-receives-fda-orphan-drug-designation-for-the-treatment-of-ovarian-cancer

- Orphan drug designation for pancreatic cancer
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-receives-fda-orphan-drug-designation-for-kevetrin-for-the-treatment-of-pancreatic-cancer

- Orphan drug designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-receives-fda-orphan-drug-designmation-for-kevetrin-for-the-treatment-of-retinoblastoma

- Rare pediatric disease designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-receives-rare-pediatric-disease-designation-from-fda-for-kevetrin-for-the-treatment-of-retinoblastoma

Brilacidin

- B-UP positive top-line data (Phase 2 POC)
http://www.ipharminc.com/press-release/2017/7/13/innovation-pharmaceuticals-phase-2-poc-trial-for-inflammatory-bowel-disease-achieves-induction-of-remission-in-a-majority-of-patients-treated-with-brilacidin

- B-OM encouraging interim data (Phase 2)
http://www.ipharminc.com/press-release/2017/3/27/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-severe-oral-mucositis-om-in-head-and-neck-cancer-patients-high-potential-for-preventative-treatment

- B-ABSSSI positive top-line data (Phase 2b)
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin

- QIDP designation for B-ABSSSI
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda

- Fast track designation for B-OM
http://www.ipharminc.com/press-release/2016/11/16/fda-grants-fast-track-designation-to-cellceutixs-brilacidin-om-for-oral-mucositis

- MTA extension for prophylactic testing in implanted devices
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-completes-lab-testing-of-brilacidin-for-planned-phase-3-trial-for-acute-bacterial-skin-and-skin-structure-infections

- Formulation stable at room temperature
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-breakthrough-in-the-formulation-of-novel-antibiotic-brlaicidin-plans-studies-to-treat-diabetic-foot-ulcers

- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/AAC.02955-14#corresp-1

Prurisol

- Positive top-line data (Phase 2a)
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint

- Positive primary endpoint (Phase 1)
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-anti-psoriasis-drug-prurisol-meets-primary-endpoint-of-clinical-trial

- 505(b)(2) pathway
http://www.ipharminc.com/press-release/2016/11/17/cellceutix-informed-by-fda-that-505b2-approval-would-be-an-acceptable-approach-for-its-psoriasis-drug

Clinical Trials

1. K-OC (Phase 2a, Recruiting)
https://clinicaltrials.gov/ct2/show/NCT03042702?term=cellceutix&rank=1

2. P (Phase 1, Completed)
https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2

3. B-OM (Phase 2, Active, not recruiting)
https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3

4. P (Phase 2a, Completed)
https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=4

5. P (Phase 2b, Active, not recruiting)
https://clinicaltrials.gov/ct2/show/NCT02949388?term=cellceutix&rank=5

6. B-ABSSSI (Phase 2b, Completed)
https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=6

7. K (Phase 1, Completed)
https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=7

8. B-UP (Phase 2 POC, Completed)
http://www.ipharminc.com/press-release/2016/11/10/cellceutix-receives-update-on-first-patient-enrollment-in-phase-2-proof-of-concept-study-of-brilacidin-for-ulcerative-proctitis



Recent Interviews

- 2017 Q3 Conference Call Transcript
https://seekingalpha.com/article/4080068-innovation-pharmaceuticals-ipix-ceo-leo-ehrlich-q3-2017-results-earnings-call-transcript

- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellceutix-corporation-ctix-ceo-leo-ehrlich-q1-2017-results-earnings-call-transcript

- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino

- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cellceutix-pipeline-continues-to-hit-milestone-after-milestone

- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a-small-cap-biotech-with-big-ideas-for-acute-infections-and-cancers-cellceutixs-leo-ehrlich-and-dr-daniel-jorgensen

Corporate Overview

- BioCentury NewsMakers Conference https://static1.squarespace.com/static/5715352e20c647639137f992/t/59b2f34946c3c498ebfe112e/1504899917915/IPIX+Company+Presentation+BioCentury+NewsMakers+Conference++8Sep2017.pdf

- Drug Discovery and Therapy World Congress
https://static1.squarespace.com/static/5715352e20c647639137f992/t/596cac7df14aa1a6e7118ed8/1500294274057/IPI+DDTWC+Brilacidin+presentation+%28final-u%29+13Jul2017.pdf

- July 2017
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5967d1c92994ca6bed362ade/1499976142099/2017+July+IPIX+Corporate+Overview.pdf

Patents

- Kevetrin
https://www.google.com/patents/US8338454

- Brilacidin
https://www.sec.gov/Archives/edgar/data/1355250/000147793214002418/ctix_ex1037.htm
https://www.google.com/patents/US20160243117
https://www.google.com/patents/EP2709619A2

- Prurisol
https://www.google.com/patents/WO2013103601A1

MP Advisors Report

https://drive.google.com/file/d/0Bz15O4eaX-asWVpoclB2WUhENFk/view

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product